sen0014196
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01521832)
Timeline
Indications
Studied for
Mechanism of action
- NAD-dependent deacetylase sirtuin 1INHIBITOR
SIRT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide
- ex 527
- ex-527
- ex527 cpd
- selisistat
- sen0014196
- sen0014196
- sen0014196
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01485965 | Phase 1 | Nov 1, 2011 | Siena Biotech S.p.A., Wake Forest University |
| NCT01521585 | Phase 2 | Nov 1, 2011 | Siena Biotech S.p.A. |
| NCT01485952 | Phase 1 | Mar 1, 2011 | European Huntington's Disease Network, Siena Biotech S.p.A. |
| NCT01521832 | Phase 1 | Oct 1, 2009 | Covance, Siena Biotech S.p.A. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Siena Biotech S.p.A. | For profit | 4 | 4 | 2 | 2009 |
| Covance | For profit | 1 | 0 | 1 | 2009 |
| European Huntington's Disease Network | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Wake Forest University | Academic/Hospital | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1